• Explore /
  • Poster
  • / A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade.

A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade.

Abstract Poster

Authors

Elshad Hasanov

Elshad Hasanov

The Ohio State University Comprehensive Cancer Center - The James, Columbus, OH

Elshad Hasanov , Hans J. Hammers , Daniel J. George , Brian I. Rini , Katy Beckermann , Joshua David Palmer , Amir Mortazavi , Roserika Brooks , Travis Solley , Lauren Michelle Wood , Naomi B. Haas , David F. McDermott , Ulka N. Vaishampayan , Eric Jonasch

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

N/A

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS497)

DOI

10.1200/JCO.2024.42.4_suppl.TPS497

Abstract #

TPS497

Poster Bd #

M18

Abstract Disclosures

Similar Posters

First Author: Chung-Han Lee

First Author: Manuel Rodrigues

First Author: Maliheh Mohamadpour

First Author: Robin Kate Kelley